Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Cash from Operations (2017 - 2025)

Historic Cash from Operations for Autolus Therapeutics (AUTL) over the last 9 years, with Q3 2025 value amounting to -$67.9 million.

  • Autolus Therapeutics' Cash from Operations rose 1152.07% to -$67.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$254.2 million, marking a year-over-year decrease of 3158.31%. This contributed to the annual value of -$206.3 million for FY2024, which is 4168.23% down from last year.
  • Latest data reveals that Autolus Therapeutics reported Cash from Operations of -$67.9 million as of Q3 2025, which was up 1152.07% from -$72.8 million recorded in Q2 2025.
  • In the past 5 years, Autolus Therapeutics' Cash from Operations registered a high of -$9.2 million during Q4 2021, and its lowest value of -$76.7 million during Q3 2024.
  • For the 5-year period, Autolus Therapeutics' Cash from Operations averaged around -$42.0 million, with its median value being -$37.9 million (2024).
  • As far as peak fluctuations go, Autolus Therapeutics' Cash from Operations skyrocketed by 6697.44% in 2021, and later tumbled by 9095.25% in 2024.
  • Autolus Therapeutics' Cash from Operations (Quarter) stood at -$9.2 million in 2021, then plummeted by 59.05% to -$14.6 million in 2022, then tumbled by 70.49% to -$24.8 million in 2023, then plummeted by 52.76% to -$37.9 million in 2024, then tumbled by 78.99% to -$67.9 million in 2025.
  • Its Cash from Operations was -$67.9 million in Q3 2025, compared to -$72.8 million in Q2 2025 and -$75.6 million in Q1 2025.